SecBot SecBot

IMCR drug pipeline

Immunocore Holdings plc · 1 rated drug
$29.94
−1.8% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.

KIMMTRAK tebentafusp Updated Sep 4

What to watch

The key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.

Bull case
  • KIMMTRAK is the first and only FDA-approved T cell engager (ImmTAC) for a solid tumor, approved for metastatic uveal melanoma in January 2022, a rare cancer with no prior approved therapies.
  • Five-year overall survival data from the Phase 3 trial showed KIMMTRAK doubled survival rates (16% vs 8% in control arm), the longest follow-up for any T cell engager in a solid tumor.
  • Revenue is growing: FY2025 net sales of $400M (+29% YoY), Q2 2026 revenue of $115.9M (+18% YoY), with $880M cash providing deep runway.
Bear case
  • KIMMTRAK is Immunocore's sole revenue source, any sales disruption, pricing pressure, or competitive threat would directly hit financials (Q2 2026 8-K shows net loss of $0.8M).
  • Revenue growth is decelerating: FY2025 grew 29% YoY to $400M, but Q2 2026 grew only 18% YoY to $115.9M, and management expects moderating growth in 2026.
  • The TEBE-AM Phase 3 trial in cutaneous melanoma is a binary risk, if it fails, the stock could drop sharply given the high short interest and single-product concentration.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
KIMMTRAKSafety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaPhase 2Completed · results378Oct 13, 2020